Moreover, the wide distribution of TRPM3 ion channels in the body suggests that their compromised function may contribute to signs and symptoms of ME/CFS and therefore treatment with LDN may have a therapeutic role. This evidence concerns the gene TRPM3 and myalgic encephalomeyelitis/chronic fatigue syndrome.